Few Q1 Bright Spots For AstraZeneca Puts Pressure On The Pipeline
Executive Summary
AstraZeneca faced commercial challenges in categories like diabetes, cardiovascular disease and respiratory disease during the quarter. FDA action on durvalumab for cancer and benralizumab for asthma are among important milestones ahead.
You may also be interested in...
Keeping Track: Neurology And Breakthroughs Stay In Spotlight As US FDA Approves Radicava, Imfinzi; TaiMed Submits Ibalizumab
The latest drug development news and highlights from our Performance Tracker.
AstraZeneca’s ZS-9 Delay In US Gives Veltassa An Edge
FDA issued a second complete response letter to AstraZeneca’s NDA for ZS-9 for hyperkalaemia, a potential blockbuster that would compete against Vifor Pharma’s Veltassa.
AstraZeneca's Lynparza Looks To Hang On To Lead, With Tesaro's Niraparib On The Way
Tesaro's niraparib has an advantage over other PARP inhibitors in that it has been tested successfully in ovarian cancer patients with and without BRCA mutations, but AstraZeneca thinks it may have a case for broad labeling in this population.